We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Introduction: France Biotech & LES France (Mathieu Losguardi (Temisis) & Frédéric Portal (Bird & Bird)
- Roundtable 1 - Partnership agreements: a tool for HealthTech companies to accelerate strategic development
o Sophie Binay; General Manager and Scientific Director at Acticor Biotech
o Cyrille Chapon; Director of Technology Transfer at Ouest Valorisation
o Aurélie Grienenberger; Chief Business Officer at Eligo Biosciences
o Moderator: Mathieu Losguardi; CEO Temisis Therapeutics
- Roundtable 2 – IP valuation : valuation and financial structuring
o Véronique Blum; President at AMAVI
o Caroline de Mareuil-Villette; Founding Partner at Icosa
o Moderator: Frédéric Portal; Lawyer, Counsel at Bird & Bird
- Roundtable 3 - Due diligence: key topics, best practices and pitfalls to avoid in IP
o Antonio Borderia, Executive Vice President Business Development at Adlin Science
o Mehdi Chelbi, CEO and co-founder of BiPER Therapeutics
o Emmanuelle Trombe, Attorney, Partner at McDermott Will & Emery
o Moderator: Matthieu Lebrun, Head of Global Out-Licensing Activities at Sanofi
